The incidence and magnitude of fibrinolytic activation in trauma patients: A rebuttal

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 7, 2013, Pages 1435-1437

  Ramos, C R ^a   Moore, E E ^a,b   Manco Johnson, M L ^a   Silliman, C C ^a   Chapman, M C ^a   Banerjee, A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; TRANEXAMIC ACID;

BLEEDING; BLOOD CLOTTING DISORDER; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; INJURY; INJURY SEVERITY; LETTER; MORTALITY; PRIORITY JOURNAL;

BLOOD COAGULATION DISORDERS; FEMALE; FIBRINOLYSIS; HUMANS; MALE; WOUNDS AND INJURIES;

EID: 84880409778     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12240     Document Type: Letter

References (15)

1. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38: 185-93.
2. Pruitt BA, Jr. Combat casualty care and surgical progress. Ann Surg 2006; 243: 715-29.
3. Floccard B, Rugeri L, Faure A, Saint Denis M, Boyle EM, Peguet O, Levrat A, Guillame C, Marcotte G, Vulliez A, Hautin E, David JS, Negrier C, Allaouchiche B. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury 2012; 43: 26-32.
4. CRASH-2 Trial Collaborators (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23-32.
5. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'ath HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, Maccallum PK, Brohi K. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013; 11: 307-14.
6. Kowalski E, Kopeć M, Niewiarowski S. An evaluation of the euglobulin method for the determination of fibrinolysis. J Clin Pathol 1959; 12: 215-8.
7. Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112: 329-37.
8. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW Jr, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 61: 888-96.
9. von Kaulla KN, Kaye H, von Kaulla E, Marchioro TL, Starzl TE. Changes in blood coagulation, before and after hepatectomv or transplantation in dogs and man. Arch Surg 1966; 92: 71-9.
10. ® 5000 System User Manual. P/N 06-510-US, Manual revision: AC. 28 Niles, IL: Haemonetics Corporation, Haemoscope Division, 2010.
11. 3 integrin-dependent protein tyrosine dephosphorylation. J Biol Chem 2001; 276: 6703-10.
12. Katori N, Tanaka KA, Szlam F, Levy JH. The Effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 2005; 100: 1781-5.
13. Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Thornton D, Collen D. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. Thromb Res 1988; 50: 121-33.
14. Hoffmann JJ, Vijgen M. Prevention of in vitro fibrinogenolysis during laboratory monitoring of thrombolytic therapy with streptokinase or APSAC. Blood Coagul Fibrinolysis 1991; 2: 279-84.
15. Hoffmann JJ, Kops O. Inhibition of desmoteplase-induced fibrinolytic activity in vitro. J Thromb Thrombolysis 2005; 20: 23-6.